## In the Specification:

On page 4, above the section "Summary of the Invention", please amend by adding the following text:

"Figures 5-12 show the effect of varying the chemical structure of a number compounds according to the present invention on biological activity.

Figure 13 shows the effect of compounds on cell growth.

Figure 14 shows the effect of compounds on the number of viable cells."

On page 37, please delete the table and change the text in the following paragraph:

"As shown above in Figure 13, the compounds derived from the linear acetylene compounds, AC22 and K1P, are inhibitory to the 32DtetP210bcrabl cell line at 1 micromolar. AC22 also inhibits the 32Dtet cell line at a similar concentration. The effect of these compounds were also studied in combination with Imatinib (Gleevec or STI-571) to determine whether the compound had an additive or synergistic effect with Imatinib in inhibiting P210bcrabl dependent cell growth. As shown above, the inhibition of the combination of AC19 and Imatinib (STI571) at a concentration of 10 nanomolar of each drug (15% inhibition) is less than the sum of the inhibitory effect of both drugs alone (25%). When compound AC22 or K1P are added in combination with Imatinib to the culture of the 32DtetP210bcrabl cell line at 10 nanomolar concentration of both drugs, there is inhibition of the growth of the P210bcrabl dependent proliferation (80%) This is greater than the sum of the inhibition that is seen when the drugs (Imatinib inhibits 25% and AC22 inhibits 10%) are used separately. A similar synergism is seen for K1P and AC19: 45% inhibition together and 25% when used alone."

On pages 38-39, please delete the MTS assay tables and add to the text in the first paragraph of page 38 as follows:

"This cell proliferation assay was performed using MTS tetrazolium (Cell titer96 Aqueous; Promega, Madison, WI), which measure numbers of viable cells. Between  $2x10^3$  and  $2x10^4$  STI-resistant cells are washed twice in RF-10 and plated in

quadruplicate in the wells of a microtiter plate in 100µl of RF-10 medium supplemented with various doses of test compounds (See Figure 14). Controls using the same concentration of Imatinib without cells were set up in parallel. The plate is then incubated for 72 hours at 37 C in a humidified 5% CO2 atmosphere. Twenty microliters of MTS were then added to the wells and the plate was incubated for three hours. Then the absorbance was recorded at 490-nm wavelength with a microplate autoreader (Spectramax). Results are expressed as the mean optical density of the 4-well set of each compound dose. All experiments were repeated at least 3 times."